In this posthoc analysis , patients with early RA who received MTX monotherapy or ADA + MTX in the PREMIER study were categorized based on clinical responses at 3 and 6 months [ American College of Rheumatology response , 28-joint Disease Activity Score ( DAS28 ) - C-reactive protein ( CRP ) improvement and targets ] .